Comparison · NCT04735432-sae
Efgartigimod PH20 SC vs Efgartigimod IV: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Efgartigimod PH20 SC vs Efgartigimod IV: serious adverse events. Trial comparisons, record NCT04735432-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04735432-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.145 | 0.0756 | 0.262 | wilson | |
| Risk in group 2 | 0.0727 | 0.0286 | 0.173 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0727 | -0.0492 | 0.197 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 2 | 0.639 | 6.26 | log | |
| Odds ratio, group 1 over group 2 | 2.17 | 0.613 | 7.68 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Efgartigimod PH20 SC than on Efgartigimod IV | 13.8 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Efgartigimod PH20 SC | Patients receiving efgartigimod PH20 subcutaneous (SC) treatment~efgartigimod PH20 SC: Subcutaneous injection with efgartigimod PH20 SC | 8 | 55 | EG000 |
| Group 2 | Efgartigimod IV | Patients receiving efgartigimod intravenous (IV) treatment~efgartigimod IV: Intravenous infusion of efgartigimod | 4 | 55 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- up to 12 weeks (throughout the treatment period)
Source ClinicalTrials.gov
Trial
- Title
- Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis
- NCT number
- NCT04735432
- Phases
- PHASE3
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- efgartigimod PH20 SC, efgartigimod IV
- Lead sponsor
- argenx
- Results first posted
- 2023-02-28
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04735432?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04735432-sae